肝细胞癌患者血清和肝组织microRNAlet-7水平及其与临床预后的关系*

doi:10.3969/j.issn.1672-5069.2018.03.029

摘要/Abstract

摘要： 目的研究肝细胞癌（HCC）患者外周血和癌组织microRNAlet-7（let-7a和let-7b）水平变化及其临床意义。方法 2015年4月~2016年6月在我院治疗的54例HCC患者和同期来我院进行体检的52例健康人,取血清,并取患者手术后癌组织和癌旁肝组织,采用实时荧光定量逆转录聚合酶链反应（qRT-PCR）法检测let-7a和let-7b水平。结果 qRT-PCR检测结果显示,HCC患者血清let-7a水平为（0.6±0.4）,显著低于健康人[（1.1±0.4）,P<0.05],血清let-7b水平为（0.3±0.1）,也显著低于健康人[（0.7±0.2）,P<0.05];HCC患者癌组织let-7a水平为（0.3±0.1）,显著低于癌旁组织[（0.6±0.1）,P<0.05],let-7a在HCC组织水平比癌旁组织下调了2.17倍,HCC组织let-7b水平为（0.4±0.2）,也显著低于癌旁组织[（1.3±0.4）,P<0.05],let-7b在HCC组织水平比癌旁组织下调了3.33倍;20例有癌栓形成患者血清let-7a水平为（0.4±0.2）,显著低于34例无癌栓形成患者的[（0.8±0.5）,P<0.05],血清let-7b为（0.1±0.1）,也显著低于无癌栓形成患者的[（0.5±0.1）,P<0.05],而不同年龄、不同性别、血清AFP水平高低、肿瘤大小、不同细胞分化程度和TNM分期及有无肿瘤血管浸润患者血清let-7a和let-7b水平无显著性差异（P>0.05）;不同年龄、性别、血清AFP水平、肿瘤大小、细胞分化、TNM分期和有无血管浸润或癌栓形成的HCC患者癌组织let-7a和let-7b水平均无显著性差异（P>0.05）。结论 HCC患者血清和肿瘤组织let-7a和let-7b呈异常低水平状态,肿瘤组织let-7a和let-7b水平也远低于癌旁肝组织,其临床意义还有待进一步探讨。

关键词: 肝细胞癌, 癌组织, 病理学, microRNAlet-7

Abstract: Objective To investigate serum and hepatic tissue microRNAlet-7 （let-7a and let-7b） levels and its clinical implication in patients with hepatocellular carcinoma （HCC）. Methods 54 patients with HCC and 52 healthy persons were recruited in our hospital between April 2015 and June 2016,and all the patients were confirmed by histopathological examination. Real-time fluorescence quantitative reverse transcriptase polymerase chain reaction（qRT-PCR） was applied to detect let-7a and let-7b in sera,cancerous tissues and its adjacent liver tissues. Results The results of qRT-PCR detection showed that serum let-7a level in patients with HCC was （0.6±0.4）,much lower than [（1.1±0.4）,P<0.05],and serum let-7b level was （0.3±0.1）,also significant lower than [（0.7±0.2）,P<0.05] in healthy persons;hepatic cancerous tissue let-7a level in patients with HCC was（0.3±0.1）,much lower than [（0.6±0.1）,P<0.05] in its adjacent liver tissues,and the cancerous let-7a level decreased by 2.17 times lower than in the adjacent liver tissues;hepatic cancerous let-7b level in patients with HCC was （0.4±0.2）,also much lower than[（1.3±0.4）,P<0.05] in its adjacent liver tissues,and the cancerous let-7b level decreased by 3.33 lower than in its adjacent liver tissues;serum let-7a level in 20 HCC patients with portal tumor thrombus formation was（0.4±0.2）,much lower than[（0.8±0.5）,P<0.05] in 34 HCC patients without, and serum let-7b level was（0.1±0.1）,also significantly lower than [（0.5±0.1）,P<0.05] in patients without,while serum let-7a and let-7b levels in patients with different age,gender,serum AFP levels,sizes of tumor, tumor differentiations,TNM stages and with or without tumor invasion were not significantly different（P>0.05）;cancerous tissue let-7a and let-7b levels in patients with different age,gender,serum AFP levels,sizes of tumor,tumor differentiations,TNM stages,with or without tumor invasion and portal tumor thrombus formation were not significantly different（P>0.05）. Conclusion sSerum and tumor tissue let-7a and let-7b levels decrease,and tumor tissue let-7a and let-7b levels are even lower than in its adjacent liver tissues,which hints what is still a problem and warrants further investigations in the future.

Key words: Hepatocellular carcinoma, Cancerous tissues, Pathology, MicroRNA let-7

张金莲, 蔡兆根, 吴琼, 秦燕子, 王梦慧, 董修芹. 肝细胞癌患者血清和肝组织microRNAlet-7水平及其与临床预后的关系*[J]. 实用肝脏病杂志, 2018, 21(3): 435-438.

Zhang Jinlian, Cai Zhaogen, Wu Qiong, et al. Serum and hepatic tissue microRNAlet-7 levels and its clinical implication in patients with hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 435-438.

参考文献

[1] 李小杉,肖静,高月霞. 原发性肝癌患者生存质量研究新进展. 实用肝脏病杂志,2011,14(3):236-238.
[2] Lee Y S,Dutta A.The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Gen Dev,2007,21(9):1025.
[3] 郝清亚,王以浪,姚登福,等. 肝癌患者血清microRNA-21水平变化. 实用肝脏病杂志,2014,17(1):68-70.
[4] Neofytou K,Smyth EC,Giakoustidis A,et al.Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases,and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol,2014,31(10):239-248.
[5] Sampson VB,Rong NH,Han J,et al.MicroRNA let-7a down-
regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res,2007,67(20):9762.
[6] Shi W,Zhang Z,Yang B,et al.Overexpression of microRNA let-7 correlates with disease progression and poor prognosis in hepatocellular carcinoma. Medicine,2017,96(32):e7764.
[7] 陈勇治,舒健,王俊,等. 肝细胞肝癌患者血清microRNAlet-7a水平的变化及意义. 中国普通外科杂志,2017,26(7):889-894.
[8] Barh D,Malhotra R,Ravi B,et al.Micrornalet-7:an emerging next-generation cancer therapeutic. Curr Oncol,2010,17(1):70-80.
[9] Tsang WP,Kwok TT.Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis,2008,13(10):1215.
[10] Nadiminty N,Tummala R,Lou W,et al.MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem,2012,287(2):1527.
[11] Nadiminty N,Tummala R,Lou W,et al.MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. Plos One,2012,7(3):e32832.
[12] 许文景,黄冬云,陈平,等. MicroRNA-let-7 a在肺癌患者中的表达及其抑癌机制的探讨. 中国免疫学杂志,2016,32(2):234-238.
[13] Sureban SM,May R,Ramalingam S,et al.Selective blockade of DCAMKL-1 results in tumor growth arrest by a let-7a microRNA-dependent mechanism. Gastroenterology,2009,137(2):649.
[14] Long XB,Sun GB,Hu S,et al.Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Oncol Rep,2009,22(5):1189.
[15] Takamizawa J,Konishi H,Yanagisawa K,et al.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res,2004,64(11):3753-3756.
[16] Lee HY,Mohammed KA,Kaye F,et al.Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibits tumor growth in lung cancer. Int J Nanomedicine,2013,2013(Issue 1):4481-4494.
[17] Ruzzo A,Graziano F,Vincenzi B,et al.High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist,2012,17(6):823-829.
[18] Jeong HC,Kim EK,Lee JH,et al.Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Rep,2011,4(2):383.
[19] Canestrari E,Ruzzo A,Vincenzi B,et al.Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR. J Clin Oncol,2011,29(suppl 15):3635-3635.
[20] Suzuki E,Ooka Y,Chiba T,et al.Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clin J Gastroenterol,2015,8(1):41-46.
[21] Joneshall YL,Kozik A,Nakatsu C.Correction: ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease. Plos One,2015,10(3):e0119441.
[22] Lu Y,Huang S,Li P,et al.Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer. Exp Ther Med,2015,9(5):2003-2007.